Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

RecruitingOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Sacubitril/ValsartanHypertensionObesity
Interventions
DRUG

Sacubitril / Valsartan Oral Tablet [Entresto]

There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.

DRUG

ACEI/ARB

"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."

Trial Locations (1)

100050

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER